Skip to content

Clinical Study on the Efficacy and Safety of Omadacycline in the Treatment of Brucellosis

Clinical Study on the Efficacy and Safety of Omadacycline in the Treatment of Brucellosis

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099844
Enrollment
Unknown
Registered
2025-03-31
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brucellosis

Interventions

The group with the combination of omadacycline:no
The group with the combination of Doxycycline:

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Voluntarily sign the informed consent form. 2. The age should be >= 18 years old, and there is no limitation on gender or ethnicity. 3. Meet the diagnostic criteria for brucellosis in the 2019 edition of the "Expert Consensus on the Diagnosis and Treatment of Brucellosis" in China, and have no complications; 4. Have not received any treatment for brucellosis in the past.

Exclusion criteria

Exclusion criteria: 1. Pregnant women or women who are breastfeeding; 2. Those suspected of having impaired liver and kidney functions, as well as those with mental and central nervous system diseases. 3. It is suspected that the disease is caused by pathogens that may have developed resistance to the tested drugs.

Design outcomes

Primary

MeasureTime frame
Clinical effective rate;

Secondary

MeasureTime frame
Time for clinical symptoms to disappear;The occurrence of adverse drugs;

Countries

China

Contacts

Public ContactYingli He

The First Affiliated Hospital of Xi'an Jiaotong University

heyingli2000@xjtu.edu.cn+86 29 85324016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026